throbber
History of Changes for Study: NCT00519285
`
`Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE)
`
`Latest version (submitted June 21, 2016) on ClinicalTrials.gov
`
`A study version is represented by a row in the table.
`
`Select two study versions to compare. One each from columns A and B.
`
`Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only
`applies to the Protocol section of the study.
`
`Click "Compare" to do the comparison and show the differences.
`
`Select a version's Submitted Date link to see a rendering of the study for that version.
`
`The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
`
`Hover over the "Recruitment Status" to see how the study's recruitment status changed.
`
`Study edits or deletions are displayed in red .
`
`Study additions are displayed in green .
`
`Study Record Versions
`
`Version
`
`A
`
`B
`
`Submitted Date
`
`Changes
`
`1
`
`2
`
`3
`
`August 21, 2007 None (earliest Version on record)
`
`December 31, 2007 Contacts/Locations, Study Status and Sponsor/Collaborators
`
`April 25, 2008 Study Status and Contacts/Locations
`
`Exhibit 2078
`Page 01 of 13
`
`

`

`Version
`
`A
`
`B
`
`Submitted Date
`
`Changes
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`June 2, 2008 Study Status
`
`August 21, 2008 Arms and Interventions, Outcome Measures, Study Design and Study Status
`
`January 12, 2009 Study Status and Study Identification
`
`July 3, 2009 Contacts/Locations, Study Status and References
`
`August 13, 2009 Contacts/Locations, Study Status and Study Identification
`
`January 29, 2010 Contacts/Locations and Study Status
`
`February 2, 2010 Study Status and Contacts/Locations
`
`February 12, 2010 Recruitment Status, Study Status and Contacts/Locations
`
`August 30, 2011 Sponsor/Collaborators, Study Status and Contacts/Locations
`
`April 16, 2012 Recruitment Status, Study Status, Outcome Measures, Study Design and Study Description
`
`April 20, 2012 Study Status
`
`August 2, 2013 Outcome Measures, Arms and Interventions, Study Status, Study Identification, Study Description, Results,
`References, Eligibility and Oversight
`
`June 21, 2016 Study Status and Baseline Characteristics
`
`Compare
`
` Comparison Format:
`
` Merged
` Side-by-Side
`
`Scroll up to access the controls
`
`Study NCT00519285
`Submitted Date: August 21, 2007 (v1)
`
`Exhibit 2078
`Page 02 of 13
`
`

`

` Study Identification
`
`Unique Protocol ID: EFC6546
`
`Brief Title: Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
`(VENICE)
`Official Title: A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus
`Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic
`Androgen-Independent Prostate Cancer
`
`Secondary IDs: AVE0005
`
` Study Status
`
`Record Verification: August 2007
`
`Overall Status: Recruiting
`
`Study Start: August 2007
`
`Primary Completion:
`
`Study Completion:
`
`First Submitted: August 21, 2007
`
`August 21, 2007
`
`First Submitted that
`Met QC Criteria:
`First Posted: August 22, 2007 [Estimate]
`
`Last Update Submitted that
`Met QC Criteria:
`Last Update Posted: August 22, 2007 [Estimate]
`
`August 21, 2007
`
`Exhibit 2078
`Page 03 of 13
`
`

`

` Sponsor/Collaborators
`
`Sponsor: Sanofi
`
`Responsible Party:
`
`Collaborators: Regeneron Pharmaceuticals
`
` Oversight
`
`U.S. FDA-regulated Drug:
`
`U.S. FDA-regulated Device:
`
`Data Monitoring:
`
` Study Description
`
`Brief Summary: The primary objective of the study is to demonstrate an improvement of overall survival in patients treated
`with aflibercept versus placebo, in patients receiving docetaxel/ prednisone.
`
`Main secondary endpoints gather prostate-specific antigen (PSA) response, pain response,time to
`occurrence of skeletal related events and progression free survival (PFS), as well as safety,
`pharmacokinetics and immunogenicity.
`
`Detailed Description:
`
`Exhibit 2078
`Page 04 of 13
`
`

`

` Conditions
`
`Conditions: Prostatic Neoplasms
`Neoplasm Metastasis
`Keywords: metastatic
`prostate
`cancer
`
` Study Design
`
`Study Type: Interventional
`
`Primary Purpose: Treatment
`
`Study Phase: Phase 3
`
`Interventional Study Model: Parallel Assignment
`
`Number of Arms:
`
`Masking: Double (masked roles unspecified)
`
`Allocation: Randomized
`
`Enrollment: 1200 [Anticipated]
`
` Arms and Interventions
`
`Intervention Details:
`
`Drug: aflibercept (VEGF Trap)
`
`Exhibit 2078
`Page 05 of 13
`
`

`

` Outcome Measures
`
`Primary Outcome Measures:
`
`Secondary Outcome Measures:
`
`1. Overall survival
`
`1. PSA measurement, pain measurement, occurrence of skeletal related events
`
`Exhibit 2078
`Page 06 of 13
`
`

`

` Eligibility
`
`Minimum Age: 18 Years
`
`Maximum Age:
`
`Sex: Male
`
`Gender Based:
`
`Accepts Healthy Volunteers: No
`
`Criteria: Inclusion Criteria:
`
`Histologically- or cytologically-confirmed prostate adenocarcinoma
`Metastatic disease
`Progressive disease while receiving hormonal therapy or after surgical castration
`Effective castration
`
`Exclusion Criteria:
`
`Prior cytotoxic chemotherapy for prostate cancer, except estramustine and except
`adjuvant/neoadjuvant treatment completed > 3 years ago
`Prior treatment with VEGF inhibitors or VEGF receptor inhibitors
`Eastern Cooperative Oncology Group performance status > 2
`
`The above information is not intended to contain all considerations relevant to a patient's potential
`participation in a clinical trial.
`
` Contacts/Locations
`
`Central Contact Person: Public registry ICD
`Email: GV-Contact-us@sanofi-aventis.com
`Locations: United States, New Jersey
`
`Exhibit 2078
`Page 07 of 13
`
`

`

`Sanofi-Aventis Administrative Office
`[Recruiting]
`Bridgewater, New Jersey, United States, 08807
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Argentina
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Buenos Aires, Argentina
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Australia, New South Wales
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Cove, New South Wales, Australia
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Belgium
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Diegem, Belgium
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Brazil
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Sao Paulo, Brazil
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Canada, Quebec
`
`Exhibit 2078
`Page 08 of 13
`
`

`

`Sanofi-Aventis Administrative Office
`[Recruiting]
`Laval, Quebec, Canada
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Chile
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Santiago, Chile
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Czech Republic
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Praha, Czech Republic
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Denmark
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Horsholm, Denmark
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Estonia
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Tallinn, Estonia
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`France
`
`Exhibit 2078
`Page 09 of 13
`
`

`

`Contact: +33(0)800 222 555
`
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Paris, France
`Contact:
`Germany
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Berlin, Germany
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Hong Kong
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Causeway Bay, Hong Kong
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Hungary
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Budapest, Hungary
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Italy
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Milan, Italy
`Contact: GV-Contact-us@sanofi-aventis.com
`Contact:
`Korea, Republic of
`
`Exhibit 2078
`Page 10 of 13
`
`

`

`Sanofi-Aventis Administrative Office
`[Recruiting]
`Seoul, Korea, Republic of
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Netherlands
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Gouda, Netherlands
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Poland
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Warszawa, Poland
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Portugal
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Porto Salvo, Portugal
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Russian Federation
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Moscow, Russian Federation
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Singapore
`
`Exhibit 2078
`Page 11 of 13
`
`

`

`Sanofi-Aventis Administrative Office
`[Recruiting]
`Singapore, Singapore
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`South Africa
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Midrand, South Africa
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Spain
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Barcelona, Spain
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Sweden
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Bromma, Sweden
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Switzerland
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Geneva, Switzerland
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`Taiwan
`
`Exhibit 2078
`Page 12 of 13
`
`

`

`Contact: GV-Contact-us@sanofi-aventis.com
`
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Taipei, Taiwan
`Contact:
`Turkey
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Istanbul, Turkey
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`United Kingdom, Surrey
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Guildford, Surrey, United Kingdom
`Contact:
`Contact: GV-Contact-us@sanofi-aventis.com
`
` IPDSharing
`
`Plan to Share IPD:
`
` References
`
`Links: URL: http://www.sanofi-aventis.com
`Description: Related Info
`
`
`
`Available IPD/Information:
`
`Scroll up to access the controls
`
`Scroll to the Study top
`
`U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services
`
`Exhibit 2078
`Page 13 of 13
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket